HRMY
Harmony Biosciences Holdings, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +5.3% ·
share flow -0.8% ·
net new positions 0.0%
· formula
Ownership fragmentation: more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 21.01K | $831,838 | n/a | −2 |
| Q2 2026 | 111 | +5 | 37.63M | $1.37B | +12 | −8 |
| Q1 2026 | 110 | -3 | 39.20M | $1.10B | +5 | −9 |
| Q4 2025 | 114 | +1 | 39.01M | $1.46B | +2 | n/a |
| Q3 2025 | 20 | +1 | 24.69M | $680.58M | +2 | −2 |
| Q2 2025 | 17 | -1 | 23.07M | $729.13M | +1 | −2 |
| Q1 2025 | 15 | +1 | 6.74M | $223.55M | +1 | n/a |
| Q4 2024 | 14 | -1 | 7.61M | $261.77M | n/a | −1 |
| Q3 2024 | 14 | +1 | 3.56M | $142.57M | +1 | n/a |
| Q2 2024 | 13 | n/a | 3.50M | $105.70M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 6.93M | +2.8% | $190.88M | 0.0% | ▲ Add | 2 | SEC ↗ ×16 |
| 2 | The Vanguard Group ✦ (passive) | 5.10M | -0.3% | $140.48M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 3 | Fidelity (FMR) ✦ | 3.85M | -17.9% | $106.02M | 0.0% | ▼ Trim | 2 | SEC ↗ ×4 |
| 4 | State Street Global Advisors ✦ (passive) | 1.65M | +1.5% | $45.57M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | Arrowstreet Capital ✦ | 1.30M | +42.8% | $35.70M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 1.26M | +19.3% | $34.68M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | Renaissance Technologies ✦ | 1.14M | +22.3% | $31.34M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 8 | Morgan Stanley ✦ | 847.89K | n/a | $23.37M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 9 | Goldman Sachs Group ✦ | 646.65K | n/a | $17.82M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 10 | AQR Capital Management ✦ | 355.57K | +133.9% | $9.80M | 0.0% | ▲ Add | 6 | SEC ↗ ×4 |
| 11 | JPMorgan Chase ✦ | 348.02K | n/a | $9.59M | 0.0% | n/c | 1 | SEC ↗ ×10 |
| 12 | Marshall Wace ✦ | 285.32K | -76.4% | $7.86M | 0.0% | ▼ Trim | 6 | SEC ↗ ×3 |
| 13 | Two Sigma Investments ✦ | 225.29K | -5.7% | $6.21M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 14 | Bridgewater Associates ✦ | 211.53K | New | $5.83M | 0.0% | New | 1 | SEC ↗ |
| 15 | Millennium Management ✦ | 204.51K | +598.2% | $5.64M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 16 | D. E. Shaw & Co. ✦ | 192.63K | -23.9% | $5.31M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 17 | Citadel Advisors ✦ | 68.01K | New | $1.87M | 0.0% | New | 1 | SEC ↗ |
| 18 | Gotham Asset Management ✦ | 38.90K | -2.0% | $1.07M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 19 | T. Rowe Price ✦ | 36.45K | +4.6% | $1.00M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 20 | Wellington Management ✦ | 19.27K | +22.5% | $531,136 | 0.0% | ▲ Add | 3 | SEC ↗ ×4 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Bridgewater Associates | $5.83M | 0.0% |
| Citadel Advisors | $1.87M | 0.0% |
Exited
| Point72 Asset Management | $1.07M | was 0.0% |
| Norges Bank | $351,487 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 306 holders, 54.70M shares, $1.38B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 35.85K sh · $1.54M
Officer · 800 sh · $34,400
Officer · 1.80K sh · $77,426
Officer · 22.95K sh · $989,350
Officer · 1.00K sh · $42,795
Officer · 4.50K sh · $190,114
Officer · 5.50K sh · $230,911
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology